When Paul Conyngham's rescue dog Rosie was diagnosed with advanced mast cell cancer in 2024, vets gave her one to six months to live. Conyngham, a Sydney-based AI consultant and Director of the Data Science and AI Association of Australia, decided to use the tools he knew best.
He started with ChatGPT - not to generate a cure, but as a research partner. He used it to brainstorm approaches, process genetic data, and work through the science of personalized cancer treatment. The actual heavy lifting involved DNA sequencing at the UNSW Ramaciotti Centre for Genomics, where researchers compared Rosie's healthy cells against her cancerous ones to pinpoint the specific mutations driving the tumor. Machine learning algorithms then identified potential vulnerabilities in those mutations that a vaccine could target.
From Mutations to mRNA
Working with Pall Thordarson, Director of the UNSW RNA Institute, Conyngham's team designed a bespoke mRNA vaccine tailored to Rosie's specific cancer mutations. According to Thordarson, it was the first time a personalized cancer vaccine had been designed for a dog.
Rosie received her first injection in December 2025, followed by a booster. A tennis ball-sized tumor on her leg shrank by roughly 50%. The team is now developing a second vaccine to target another tumor that didn't respond to the first round.
What ChatGPT Actually Did Here
This isn't a story about ChatGPT curing cancer. The real science came from genomic sequencing, computational biology, and mRNA vaccine design by qualified researchers at UNSW. But ChatGPT served as something it's genuinely good at: a brainstorming and analysis partner that helped a domain expert move faster through complex research territory.
The more interesting signal is the broader pipeline. DNA sequencing costs have dropped dramatically. Protein structure prediction tools like AlphaFold - Google DeepMind's system for predicting how proteins fold into 3D shapes - can model vaccine targets in hours instead of months. And large language models can help technically skilled people navigate unfamiliar scientific literature quickly.
Personalized mRNA cancer vaccines for humans are already in clinical trials at companies like Moderna and BioNTech. The fact that a single AI consultant could assemble a version of this pipeline for a dog - with university collaboration, not alone in a garage - says something about how accessible these tools are becoming for people with the right technical background.
Rosie, for her part, is still alive and receiving treatment. That alone exceeded every prognosis she was given.